

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen at the centre of the current global pandemic, causes coronavirus disease 2019 (COVID-19) 1. Our results suggest that LSC-nanodecoys can serve as a potential therapeutic agent for treating COVID-19.

In cynomolgus macaques challenged with live SARS-CoV-2, four doses of these nanodecoys delivered by inhalation promoted viral clearance and reduced lung injury. Furthermore, inhalation of the LSC-nanodecoys accelerated clearance of SARS-CoV-2 mimics from the lungs, with no observed toxicity. In mice, these LSC-nanodecoys were delivered via inhalation therapy and resided in the lungs for over 72 h post-delivery. Here we show that ACE2 nanodecoys derived from human lung spheroid cells (LSCs) can bind and neutralize SARS-CoV-2 and protect the host lung cells from infection. Angiotensin-converting enzyme 2 (ACE2) plays a fundamental role in SARS-CoV-2 pathogenesis because it allows viral entry into host cells. Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has grown into a global pandemic, and only a few antiviral treatments have been approved to date. This entry was posted in Uncategorized by admin. This testing process is crucial for the final game and it’s great to see that the community is offering support here! We would like to say thanks in advance for each application.


Therefore we unfortunately need to reject all applications after July 6. In order to do so, please send an email to and include your full name and address.Īfter July 6, we will randomly select a limited number of participants. People interested in testing can apply for the beta test between today and July 6. In order to minimize administration efforts, the number of participants is limited. After long and intensive development, we are very happy to announce that we are ready to run a closed beta test between July 14 and July 24.
